Skip to main content

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.79
-6.32 (-3.01%)
AAPL  265.15
+0.57 (0.22%)
AMD  195.27
-4.88 (-2.44%)
BAC  51.24
-1.82 (-3.43%)
GOOG  312.48
-2.42 (-0.77%)
META  642.86
-12.80 (-1.95%)
MSFT  385.46
-11.77 (-2.96%)
NVDA  189.91
+0.09 (0.05%)
ORCL  138.96
-9.12 (-6.16%)
TSLA  398.86
-12.96 (-3.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.